IS7271A - Piperdine og piperazine afleiður 2,4-disubstituted, 3,5-disubstituded and 3,4,5-sumstituted piperadines and piperazines - Google Patents

Piperdine og piperazine afleiður 2,4-disubstituted, 3,5-disubstituded and 3,4,5-sumstituted piperadines and piperazines

Info

Publication number
IS7271A
IS7271A IS7271A IS7271A IS7271A IS 7271 A IS7271 A IS 7271A IS 7271 A IS7271 A IS 7271A IS 7271 A IS7271 A IS 7271A IS 7271 A IS7271 A IS 7271A
Authority
IS
Iceland
Prior art keywords
disubstituted
sumstituted
piperadines
piperdine
piperazines
Prior art date
Application number
IS7271A
Other languages
English (en)
Inventor
John Varghese
B. Moon Joseph
R. Pulley Shon
H. Rich Daniel
L. Brown David
Jagodzinska Barbara
S. Jacobs John
Original Assignee
Elan Pharmaceuticals, Inc.
Pharmacia & Upjohn Company
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Elan Pharmaceuticals, Inc., Pharmacia & Upjohn Company filed Critical Elan Pharmaceuticals, Inc.
Publication of IS7271A publication Critical patent/IS7271A/is

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/451—Non condensed piperidines, e.g. piperocaine having a carbocyclic group directly attached to the heterocyclic ring, e.g. glutethimide, meperidine, loperamide, phencyclidine, piminodine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D211/40—Oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D211/40—Oxygen atoms
    • C07D211/42—Oxygen atoms attached in position 3 or 5
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Psychology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
  • Plural Heterocyclic Compounds (AREA)
IS7271A 2001-11-19 2004-05-19 Piperdine og piperazine afleiður 2,4-disubstituted, 3,5-disubstituded and 3,4,5-sumstituted piperadines and piperazines IS7271A (is)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US33270801P 2001-11-19 2001-11-19
US38316702P 2002-05-24 2002-05-24
PCT/US2002/037037 WO2003043987A2 (en) 2001-11-19 2002-11-19 (4-phenyl) piperidin-3-yl-phenylcarboxylate derivatives and related compounds as beta-secretase inhibitors for the treatment of alzheimer's disease

Publications (1)

Publication Number Publication Date
IS7271A true IS7271A (is) 2004-05-19

Family

ID=26988352

Family Applications (1)

Application Number Title Priority Date Filing Date
IS7271A IS7271A (is) 2001-11-19 2004-05-19 Piperdine og piperazine afleiður 2,4-disubstituted, 3,5-disubstituded and 3,4,5-sumstituted piperadines and piperazines

Country Status (21)

Country Link
US (1) US7338965B2 (is)
EP (1) EP1448200A2 (is)
JP (1) JP2005514362A (is)
KR (1) KR20050044533A (is)
AP (1) AP2004003052A0 (is)
AU (1) AU2002360403A1 (is)
BR (1) BR0214295A (is)
CA (1) CA2467749A1 (is)
CO (1) CO5580743A2 (is)
EA (1) EA200400699A1 (is)
GE (1) GEP20074045B (is)
HR (1) HRP20040550A2 (is)
IL (1) IL162079A0 (is)
IS (1) IS7271A (is)
MX (1) MXPA04004772A (is)
NO (1) NO20042580L (is)
NZ (1) NZ533158A (is)
OA (1) OA12812A (is)
RS (1) RS54204A (is)
TN (1) TNSN04088A1 (is)
WO (1) WO2003043987A2 (is)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7521481B2 (en) 2003-02-27 2009-04-21 Mclaurin Joanne Methods of preventing, treating and diagnosing disorders of protein aggregation
US7763609B2 (en) 2003-12-15 2010-07-27 Schering Corporation Heterocyclic aspartyl protease inhibitors
KR20080015079A (ko) 2005-04-08 2008-02-18 코멘티스, 인코포레이티드 베타 세크레타제 활성을 억제하는 화합물 및 이것의 사용방법
EP1816122A3 (en) * 2006-01-19 2007-09-19 Speedel Experimenta AG 3,4,5-substituted piperidines as therapeutic compounds
DK2032701T3 (da) 2006-06-23 2014-02-10 Alethia Biotherapeutics Inc Polynukleotider og polypeptider, der er inddraget i cancer
KR100679869B1 (ko) * 2006-10-27 2007-02-07 한국기계연구원 Ｄｐｆ시스템용 플라즈마 반응기와 이를 이용한 입자상물질의 저감 장치
EP2077719B1 (en) * 2006-09-21 2011-12-28 Merck Sharp & Dohme Corp. Piperidine and pyrrolidine beta-secretase inhibitors for the treatment of alzheimer's disease
KR100838645B1 (ko) * 2006-09-28 2008-06-16 한국화학연구원 베타-세크리테아제 활성을 억제하는 피페리딘 화합물
WO2008055945A1 (en) 2006-11-09 2008-05-15 Probiodrug Ag 3-hydr0xy-1,5-dihydr0-pyrr0l-2-one derivatives as inhibitors of glutaminyl cyclase for the treatment of ulcer, cancer and other diseases
WO2008065141A1 (en) 2006-11-30 2008-06-05 Probiodrug Ag Novel inhibitors of glutaminyl cyclase
EP2481408A3 (en) 2007-03-01 2013-01-09 Probiodrug AG New use of glutaminyl cyclase inhibitors
EP2865670B1 (en) 2007-04-18 2017-01-11 Probiodrug AG Thiourea derivatives as glutaminyl cyclase inhibitors
KR100894713B1 (ko) * 2007-10-08 2009-04-24 한국화학연구원 베타-세크리테아제의 활성을 저해하는 아릴피페라진이 치환된 피페리딘 유도체 또는 이의 약제학적으로 허용 가능한 염 및 이를 유효성분으로 함유하는 신경퇴행성 질환의 예방 또는 치료용 조성물
KR20110084280A (ko) 2008-11-03 2011-07-21 알레시아 바이오쎄라퓨틱스 인코포레이티드 종양 항원의 생물 활성을 특이적으로 차단하는 항체
US8486940B2 (en) 2009-09-11 2013-07-16 Probiodrug Ag Inhibitors
JP6026284B2 (ja) 2010-03-03 2016-11-16 プロビオドルグ エージー グルタミニルシクラーゼの阻害剤
EP2545047B9 (en) 2010-03-10 2015-06-10 Probiodrug AG Heterocyclic inhibitors of glutaminyl cyclase (qc, ec 2.3.2.5)
EP2560953B1 (en) 2010-04-21 2016-01-06 Probiodrug AG Inhibitors of glutaminyl cyclase
JP6050264B2 (ja) 2011-03-16 2016-12-21 プロビオドルグ エージー グルタミニルシクラーゼの阻害剤としてのベンゾイミダゾール誘導体
KR101993259B1 (ko) 2011-03-31 2019-06-27 에이디씨 테라퓨틱스 에스에이 신장 결합 항원 １에 대한 항체 및 이의 항원 결합 단편
EA201992513A1 (ru) 2012-01-09 2020-05-31 Адс Терапьютикс Са Способ лечения рака груди
PL3461819T3 (pl) 2017-09-29 2020-11-30 Probiodrug Ag Inhibitory cyklazy glutaminylowej

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3992441A (en) * 1972-12-26 1976-11-16 Pfizer Inc. Sulfamylbenzoic acids
US4248876A (en) * 1977-01-08 1981-02-03 John Wyeth & Brother Ltd. Piperidine derivatives
US5142056A (en) * 1989-05-23 1992-08-25 Abbott Laboratories Retroviral protease inhibiting compounds
GB8430581D0 (en) * 1984-12-04 1985-01-09 Ferrosan As Treatment
DE3640475A1 (de) * 1986-11-27 1988-06-09 Hoechst Sa Lab Arzneimittel auf basis von derivaten des 3,4-diphenylpiperidins, die verwendung der derivate als arzneimittel sowie neue 3,4-diphenylpiperidinderivate und verfahren zu ihrer herstellung
GB8714789D0 (en) * 1987-06-24 1987-07-29 Lundbeck & Co As H Heterocyclic compounds
IE63906B1 (en) * 1987-11-13 1995-06-14 Novo Nordisk As Azabicyclic compounds and their preparation and use
US4997836A (en) * 1988-11-11 1991-03-05 Takeda Chemical Industries, Ltd. Trisubstituted piperazine compounds, their production and use
US5510378A (en) * 1990-11-19 1996-04-23 G.D. Searle & Co. Retroviral protease inhibitors
KR100336699B1 (ko) * 1992-08-25 2002-05-13 윌리암스 로저 에이 레트로바이러스 프로테아제 저해제로서 유용한히드록시에틸아미노 술폰아미드
US5475138A (en) * 1994-07-07 1995-12-12 Pharm-Eco Laboratories Incorporated Method preparing amino acid-derived diaminopropanols
NZ315677A (en) 1995-09-07 2000-02-28 F 4-(oxyalkoxyphenyl)-3-oxy-piperidines for treating heart and kidney insufficiency
CA2280096A1 (en) 1997-02-04 1998-08-06 The Regents Of The University Of California Nanomolar, non-peptide inhibitors of cathepsin d
AU9740998A (en) * 1997-09-08 1999-03-29 F. Hoffmann-La Roche Ag Piperidine derivatives against malaria
WO1999024422A1 (en) * 1997-11-05 1999-05-20 Neurosearch A/S Azaring-ether derivatives and their use as nicotinic ach receptor modulators
CA2319077A1 (en) * 1998-01-21 1999-07-29 Yoshisuke Nakasato Chemokine receptor antagonists and methods of use therefor
GB9810671D0 (en) * 1998-05-18 1998-07-15 Pfizer Ltd Anti-pruritic agents
JP2002520316A (ja) * 1998-07-10 2002-07-09 アストラゼネカ・アクチエボラーグ ニューロキニン受容体アンタゴニストとしてのｎ−置換ナフタレンカルボキサミド
US6274735B1 (en) * 1998-08-10 2001-08-14 Hoffmann-La Roche Inc. Process and intermediates for preparation of substituted piperidines
AU769260B2 (en) 1998-10-07 2004-01-22 Georgetown University Monomeric and dimeric heterocycles, and therapeutic uses thereof
GB9904786D0 (en) * 1999-03-02 1999-04-28 Merck Sharp & Dohme Therapeutic agents
EP1361875A2 (en) * 2001-02-16 2003-11-19 Aventis Pharmaceuticals Inc. Novel heterocyclic amide derivatives and their use as dopamine d3 receptor ligands
AU2002306848A1 (en) * 2001-03-23 2002-10-08 Elan Pharmaceuticals, Inc. Methods of treating alzheimer's disease with piperidin derivates
AU2002256418A1 (en) * 2001-04-27 2002-11-11 Vertex Pharmaceuticals Incorporated Inhibitors of bace

Also Published As

Publication number Publication date
RS54204A (en) 2006-12-15
WO2003043987A3 (en) 2003-07-10
MXPA04004772A (es) 2005-06-06
US7338965B2 (en) 2008-03-04
IL162079A0 (en) 2005-11-20
CA2467749A1 (en) 2003-05-30
NZ533158A (en) 2006-09-29
OA12812A (en) 2006-07-10
BR0214295A (pt) 2004-11-09
HRP20040550A2 (en) 2006-11-30
EA200400699A1 (ru) 2004-12-30
NO20042580L (no) 2004-08-09
EP1448200A2 (en) 2004-08-25
JP2005514362A (ja) 2005-05-19
AU2002360403A1 (en) 2003-06-10
KR20050044533A (ko) 2005-05-12
TNSN04088A1 (en) 2006-06-01
WO2003043987A2 (en) 2003-05-30
US20040034031A1 (en) 2004-02-19
CO5580743A2 (es) 2005-11-30
AP2004003052A0 (en) 2004-06-30
GEP20074045B (en) 2007-02-26

Similar Documents

Publication Publication Date Title
IS7271A (is) Piperdine og piperazine afleiður 2,4-disubstituted, 3,5-disubstituded and 3,4,5-sumstituted piperadines and piperazines
IS5983A (is) Píperidín, tetrahýdrópýridín og píperzín afleiður, framleiðsla þeirra og notkun
NO20023787L (no) Piperazin- og piperidinderivater
NO20026125L (no) Tetrahydropyridin- eller piperidin-heterocykliske derivater
DE60113865D1 (de) Piperazin derivate
DE60136530D1 (de) 2,4-disubstituierte thiazolyl derivate
ATE397595T1 (de) Piperazin-derivate
EE200200567A (et) Uued piperasiini derivaadid
ATE188691T1 (de) 1-(1,2-disubstituierte piperidinyl)-4- substituierte piperazin derivate
DK1198453T5 (da) N-(indolcarbonyl-)piperazinderivater
PL355654A1 (en) Piperidine and piperazine derivatives which function as 5-ht2a
EE05386B1 (et) Ftalasinoon-piperidinoderivaadid,ÁnendeÁkasutamineÁjaÁravim
DK1131308T3 (da) Piperazin- og piperidinderivater
EE200100498A (et) 1,4-asendatud piperasiin-, 1,4-asendatud piperidiin- ja 1-asendatud 4-alkülidenüülpiperidiinühendidning nende raviotstarbeline kasutamine
NO20011436L (no) 2,2,6,6-dietyl-dimetyl-1-alkoksy-piperidin-forbindelser og deres korresponderende 1-oksider
NO20043079L (no) Piperazinderivat
DE60101386D1 (de) Piperazin- und piperidinverbindungen
NO984380D0 (no) Nye piperazin og piperidin forbindelser
DE60203481D1 (de) Piperidinderivate als neurokinin 1 antagonisten
FR2821719B1 (fr) Nouvelles compositions fongicides a base de derive de pyridylmethylbenzamide et de propamocarbe
WO2002046156A3 (en) 4,4-DISUBSTITUTED PIPERIDINES AND THEIR METHODS OF USE
NO995643D0 (no) Nye 4-substituerte piperidiner
ITMI20021328A1 (it) Nuove piperazine 1,4 - disostituite